5,750 Shares in Novo Nordisk A/S (NYSE:NVO) Purchased by Unique Wealth Strategies LLC

Unique Wealth Strategies LLC bought a new stake in shares of Novo Nordisk A/S (NYSE:NVO) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 5,750 shares of the company’s stock, valued at approximately $595,000.

A number of other large investors also recently added to or reduced their stakes in NVO. Jennison Associates LLC lifted its position in Novo Nordisk A/S by 100.3% during the 3rd quarter. Jennison Associates LLC now owns 23,419,405 shares of the company’s stock valued at $2,129,761,000 after purchasing an additional 11,727,507 shares during the period. Polen Capital Management LLC acquired a new position in Novo Nordisk A/S during the 3rd quarter valued at about $718,995,000. FMR LLC lifted its position in Novo Nordisk A/S by 122.7% during the 3rd quarter. FMR LLC now owns 12,077,501 shares of the company’s stock valued at $1,098,328,000 after purchasing an additional 6,654,614 shares during the period. Morgan Stanley increased its stake in shares of Novo Nordisk A/S by 96.5% in the 3rd quarter. Morgan Stanley now owns 9,215,098 shares of the company’s stock valued at $838,021,000 after acquiring an additional 4,526,199 shares during the last quarter. Finally, Loomis Sayles & Co. L P increased its stake in shares of Novo Nordisk A/S by 91.7% in the 3rd quarter. Loomis Sayles & Co. L P now owns 9,097,808 shares of the company’s stock valued at $827,354,000 after acquiring an additional 4,350,862 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

NVO has been the subject of a number of recent analyst reports. UBS Group initiated coverage on Novo Nordisk A/S in a research note on Tuesday, January 16th. They issued a “neutral” rating for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. BMO Capital Markets initiated coverage on Novo Nordisk A/S in a research note on Friday, April 12th. They set an “outperform” rating and a $163.00 target price for the company. Finally, Morgan Stanley initiated coverage on Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 target price for the company. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $133.60.

Novo Nordisk A/S Stock Up 0.8 %

Shares of NVO traded up $1.06 during mid-day trading on Friday, hitting $126.85. 3,312,457 shares of the company’s stock were exchanged, compared to its average volume of 3,307,405. The company has a market cap of $569.24 billion, a PE ratio of 46.89, a P/E/G ratio of 2.12 and a beta of 0.41. Novo Nordisk A/S has a 52 week low of $75.56 and a 52 week high of $138.28. The company has a 50-day simple moving average of $126.86 and a 200 day simple moving average of $112.11. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.05. The company had revenue of $9.51 billion during the quarter, compared to analysts’ expectations of $9.14 billion. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. On average, research analysts forecast that Novo Nordisk A/S will post 3.32 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were issued a $0.664 dividend. This represents a dividend yield of 0.9%. The ex-dividend date of this dividend was Friday, March 22nd. This is an increase from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s dividend payout ratio is presently 49.17%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.